Dynavax and DoD Announce Collaboration to Develop an Adjuvanted Plague Vaccine
Dynavax Technologies Corporation and the U.S. Department of Defense (DOD) today announced an agreement for approximately $22 million over two and a half years to ...
Tag: JPEO-CBRND
Rigel Awarded $16.5 Million from DoD for Phase 3 Trial of Fostamatinib in COVID-19 Patients
Rigel Pharmaceuticals, Inc. announced on Jan. 29 it has been awarded $16.5 million by the U.S. Department of Defense's (DOD) Joint Program ...
DoD Awards Funding to Pulmotect to Study Repurposed PUL-042 Against COVID-19
The Department of Defense (DOD) awarded a $6 million agreement to Pulmotect, Inc., a clinical-stage biotechnology company, to execute two ...
DoD Expands U.S. Domestic Diagnostics Capacity with $481M Cue Health Deal
Cue Health Inc. will receive an $481 Million contract from the Department of Defense (DOD), on behalf of the U.S. ...
BARDA and JPEO-CBRND Back Cepheid’s Multiplex Test for Influenza, SARS-CoV2 and RSV
During the upcoming flu season, public health and medical professionals will require diagnostic tools to determine if a patient with ...
National COVID-19 Vaccination Strategy: DoD Awards $125M to Goldbelt Security
The Department of Defense (DOD) awarded $125 million to Goldbelt Security, LLC on Aug. 31, 2020 to procure 530 million ...
Promising Results from Phase 1 Trial of Equine Encephalitis Virus Vaccine
Bavarian Nordic A/S announced today topline results from the first-in-human trial of MVA-BN WEV, a prophylactic vaccine candidate against three ...
JPEO-CBRND, BARDA Partner with SAb Biotherapeutics to Develop COVID-19 Therapeutic
A therapeutic to treat novel coronavirus disease 2019 (COVID-19) is moving forward in development through a partnership announced Apr. 1 ...
Scientists from Noblis and DoD Identify Unique Genetic Sequences of Emerging Coronavirus Threat
Scientists from Noblis and the Defense Biological Product Assurance Office (DBPAO), a component of the Joint Program Executive Office for ...
Army Medical Department Board Tests Nerve Agent Antidote Auto-Injectors
Nerve agents are the most toxic of the known chemical agents. They are hazards in both liquid and vapor states ...
FDA and DoD Sign Memorandum to Enhance Engagement on Medical Products for Servicemembers
Today, the U.S. Food and Drug Administration and the Department of Defense’s (DoD) Office of Health Affairs signed a Memorandum ...
DoD Seeks Manufacturer for Nerve Agent Anticonvulsant Autoinjectors
The Joint Program Executive Office for Chemical and Biological Defense is seeking information on the capabilities of organizations to develop ...
PRISM: Advancing Nucleic Acid Vaccine Platform Technologies
An innovative approach is being initiated by the Department of Defense, which will accelerate MCM delivery by leveraging platform technologies ...
DoD Seeks to Develop Advanced Anticholinergic with Increased Efficacy Against Nerve Agents
Therapeutic pharmaceuticals against chemical, biological, radiological and nuclear (CBRN) warfare agents are required to support the Joint Forces across a ...
Putting the Pieces Together: Solving the Burkholderia Puzzle
No definitive diagnostic test exists for Burkholderia, a category B agent caused by Burkholderia pseudomallei bacterium, which poses a threat ...
RFI – Enhanced Maritime Biological Detection (EMBD)
The Enhanced Maritime Biological Detection (EMBD) program is charged with finalizing development, and complete testing, integration and production of an ...
RFI – Defense Biological Product Assurance Office Critical Reagents
The Defense Biological Product Assurance Office (DBPAO), previously known as the Critical Reagents Program (CRP), is conducting market research on ...
Battelle Awarded 10.1M CBRN Support Contract
The U.S. Department of Defense has recently awarded a notable contract related to the field of chemical, biological, radiological and ...
DoD Seeks Medical Countermeasure Manufacturing
The U.S. Department of Defense (DoD) is conducting market research to identify vaccine developers who have advanced manufacturing platforms which ...
RFI – Bioscavenger Medical Countermeasures
The U.S. Department of Defense is seeking information from organizations on their capability to support advanced development of human butyrylcholinesterase ...
